| Zacks Company Profile for Viskase Holdings, Inc. (ENZN : OTC) |
|
|
| |
| • Company Description |
| Enzon Pharmaceuticals, Inc. is a biotechnology company. It discovers, develops, and commercializes therapeutics to treat life-threatening diseases. The Company's marketed drug products include PegIntron (R) for chronic hepatitis C; Sylatron (R) for Melanoma; Macugen (R) for neovascular age-related macular degeneration; CIMZIA (R) for Crohn's disease; Oncaspar for acute lymphoblastic leukemia; and Adagen for severe combined immunedeficiency. Enzon Pharmaceuticals, Inc. is headquartered in Piscataway, New Jersey.
Number of Employees: |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $5.75 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,234 shares |
| Shares Outstanding: 0.74 (millions) |
| Market Capitalization: $4.27 (millions) |
| Beta: -0.03 |
| 52 Week High: $12.99 |
| 52 Week Low: $3.01 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-15.78% |
-19.56% |
| 12 Week |
-4.33% |
-11.55% |
| Year To Date |
51.72% |
39.49% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
333 East Butterfield Road Suite 400
-
Lombard,IL 60148
USA |
ph: 630-874-0700
fax: 732-980-4585 |
investor@enzon.com |
http://www.enzon.com |
|
|
| |
| • General Corporate Information |
Officers
Richard L. Feinstein - Chief Executive Officer; Chief Financial Officer a
Randolph C. Read - Chairman
Jordan Bleznick - Director
Jaffray A. Firestone - Director
Stephen T. Wills - Director
|
|
Peer Information
Viskase Holdings, Inc. (CAGAQ)
Viskase Holdings, Inc. (SFD)
Viskase Holdings, Inc. (DOBQ)
Viskase Holdings, Inc. (ENZN)
Viskase Holdings, Inc. (HAMS)
Viskase Holdings, Inc. (TAVI.)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: FOOD-MEAT PRODS
Sector: Consumer Staples
CUSIP: 293904801
SIC: 2836
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 08/13/26
|
|
Share - Related Items
Shares Outstanding: 0.74
Most Recent Split Date: 3.00 (0.01:1)
Beta: -0.03
Market Capitalization: $4.27 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/13/26 |
|
|
|
| |
